Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: Crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 Å resolution

Journal of Drug Targeting

Volumn 13, Issue 2, 2005, Pages 113-119

  Singh, Rajendra Kumar ^a   Ethayathulia, A S ^a   Jabeen, Talat ^a   Sharma, Sujata ^a   Kaur, Punit ^a   Singh, Tej P ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Aspirin; Binding constant; Inflammation; Phospholipase A2

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG DESIGN; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BINDING SITES; COBRA VENOMS; CRYSTALLOGRAPHY, X-RAY; KINETICS; MODELS, MOLECULAR; PHOSPHOLIPASES A; PROTEIN BINDING;

EID: 17444413112     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400024078     Document Type: Article

References (30)

1. Cha SS, Lee D, Adams J, Kurdyla JT, Jones CS, Marshall LA, Bolognese B, Abdel-Meguid SS, Oh BH. 1996. High resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX). J Med Chem 39:3878-3881.
2. 2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 Å crystal structure. Biochemistry 41:10914-10919.
3. 2 and alpha-tocopherol at 1.8 Å resolution. J Mol Biol 320:215-222.
4. 2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr D 58:1813-1819.
5. 2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J Biol Chem 43:41079-41085.
6. Cryer B, Feldman M. 1998. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 5:413-421.
7. DeWitt DL. 1991. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta 1083:121-134.
8. Granstrom E. 1983. Prostaglandin biochemistry, pharmacy and physiological function. The prostaglandins, thromboxanes and leukotrienes. Acta Obstet Gynecol Scand Suppl 113:9-13.
9. Jones TA, Zou JY, Cowan SW, Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
10. 2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci USA 75:2955-2958.
11. Laskowski R, Macarthur M, Moss D, Thornton J. 1993. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-290.
12. 2 synthase. Nat Struct Biol 2:637-643.
13. -]. Acta Cryst B 26:2046-2054.
14. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihoods method. Acta Crystallogr D 53:240-255.
15. Navaza J. 1994. AMoRe: An automated package for molecular replacement. Acta Crystallogr A 50:157-163.
16. Nicholls A, Sharp KA, Honig B. 1991. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281-296.
17. Nieba L, Krebber A, Pluckhun A. 1996. Competition BIAcore for true affinities: Large differences from values determined from binding kinetics. Anal Biochem 234:155-165.
18. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
19. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. 1999. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 6:1905-1909.
20. Ramachandran GN, Sasisekharan V. 1968. Conformation of polypeptides and proteins. Adv Protein chem 23:713-720.
21. Roth GJ, Majerus PW. 1975. The mechanism of the effect of Aspirin on human platelets: 1 Acetylation of a particulate fraction protein. J Clin Invest 56:624-632.
22. Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE, Hartley LW, Jones ND, Mihelich ED. 1995. Structure-based design of the first potent and selective inhibitor of human nonpancreatic secretory phospholipase A2. Nat Struct Biol 6:458-465.
23. Scott DL, White SP, Browning JL, Rosa JJ, Gelb MH, Sigler PB. 1991. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudates. Science 254:1007-1010.
24. 2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl) -sn-glycero-2-phosphomethanol. Biochemistry 36:14186-14191.
25. 2. J Mol Biol 333:367-376.
26. 2 from Naja naja sagittifera (group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9 Å resolution reveals unique features. Biochemistry 40:11701-11706.
27. Sperling RI. 1995. Eicosanoids in rheumatoid arthritis. Rheum Dis Clin North Am. 3:741-758.
28. Szabo A, Stolz L, Granzow R. 1995. Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Curr Opin Struct Biol 5:699-705.
29. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin- like drugs. Nature 231:232-235.
30. White SP, Scott DL, Otwinowski Z, Gelb MH, Sigler PB. 1990. Crystal-structure of cobra-venom phospholipase A2 in a complex with a transition-state analog. Science 250: 1560-1563.